Description
An orally bioavailable, direct-acting inhibitor of HCV NS3/4A serine protease; inhibits HCV replication in stable Huh7-derived replicon cell lines infected with subgenomic genotypes 1a, 1b, 2a, 3a, 4a, and 6a (EC50s = 1, 0.21, 5.3, 19, 0.09, and 0.69 nM, respectively); inhibits replicons from clinical isolates of genotypes 1a (EC50s = 0.43 to 1.87 nM) and 1b (EC50s = 0.033 to 0.087 nM)
Formal name: (2R,6S,12Z,13aS,14aR,16aS)-N-(cyclopropylsulfonyl)-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-6-[[(5-methyl-2-pyrazinyl)carbonyl]amino]-5,16-dioxo-2-(6-phenanthridinyloxy)-cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxamide
Synonyms: ABT-450
Molecular weight: 765.9
CAS: 1216941-48-8
Purity: ≥98%
Formulation: A solid
